Michaela Liedtke, MD, Associate Professor at Stanford University Medical Center in Palo Alto, CA, discusses CAR T-cell therapy for patients with multiple myeloma. She also discusses clinical data and the current indication CAR T-cell therapies. Finally, Dr Liedtke discusses toxicities associated with CAR T-cell therapy. She also discusses how next-generation CAR T-cell therapies have been designed to overcome resistance.
Manali Kamdar, MD, clinical director of lymphoma services, University of Colorado Cancer Center, Denver, Colorado, discusses the use of circulating tumor DNA as an early predictor of outcomes…
Krina K. Patel, MD, MSc, associate professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses results from a recent study of real-world…
Rahul Banerjee, MD, assistant professor, Clinical Research Division, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, addresses the question of whether CAR T-cell therapy is a cure…
Multiple Myeloma is a cancer that affects plasma cells in bone marrow. Abnormal plasma cells produce harmful proteins, leading to anemia, bone pain, frequent infections, and kidney failure.…
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Bhavesh Mohan Lal, MD, UAMS College of Medicine, Little Rock, Arkansas, reviews a study designed to investigate the effects of prior exposure to BCMA-targeting agents on outcomes with…
Adriana Rossi, MD, assistant professor of medicine, director of CART and the Stem Cell Transplant Clinical Service at the Center of Excellence for Multiple Myeloma, Mount Sinai, New…
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses findings from one arm of the Phase 2 KarMMA-2 trial that was designed to investigate idecabtagene vicleucel in…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
